Essex Bio-Technology Ltd (1061) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Essex Bio-Technology Ltd stock HK$5.69, price HK$1.90, upside +200.0%, quality 64 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Essex Bio-Technology Ltd
1061 · HKCheap (67% below fair value) and solid company, but falling price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 20, 2026.
How to read this chart
60‑month range HK$1.82 – HK$7.12 · fair‑value band HK$3.07 – HK$7.73 · the HK$1.90 price screens below the HK$5.69 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 20, 2026.
Every Wednesday you see whether Essex Bio-Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. It operates through Ophthalmology, Surgical, and Healthcare and Partner Services segments.
Show moreShow less
The company researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration.
It offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds; and Tobramycin, Levofloxacin, Sodium Hyaluronate, Diquafosol Sodium, and Moxifloxacin Hydrochloride eye drops, as well as Iodized lecithin capsules.
The company also provides healthtech e-platform-related medical services, Beifuji spray and lyophilized powder, and Beifuxin gels to treat surface wounds.
It offers Carisolv, a dental caries removal gel; mouthwash; oral care products; portable ultraviolet phototherapy devices; PELNACTM, a collagen-based artificial dermis; SCALGENTM, a double-layered artificial dermis; bioresorbable implants for dental surgery; hydrophilic contact lens; and other medical devices for myopia control and prevention; eye-protection lamp; and defocus customized glasses.
The company develops SkQ1 eye drop, which is in the second phase 3 clinical trial; Bevacizumab ophthalmic injection for wet-AMD, which is in phase 3 clinical trial; and EB11-21148P, which is in phase 2 clinical trial, as well as new therapeutics in oncology, orthopedics, and neurology.
It has license agreements with Mitotech S.A. for a clinical trial of an ophthalmic solution containing SkQ1 for dry eye disease; and Shanghai Henlius Biotech Inc. to co-develop a pharmaceutical product that contains an anti-vascular endothelial growth factor as a drug substance, which is intended to treat macular degeneration.
The company was founded in 1990 and is headquartered in Zhuhai, China.
Stock analysis
Essex Bio-Technology Ltd (1061) currently trades at HK$1.90, while our model-based Fair Value estimate is HK$5.69, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$15.88 per share, and 23 of the 26 models we run sit above the HK$1.90 price.
Bear case: the Asset-Based group reads lowest at HK$0.9600, and 3 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$3.07 (bear) to HK$7.73 (bull), the price of HK$1.90 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Essex Bio-Technology Ltd reported revenue of HK$1.8B in FY2025 versus HK$1.6B in FY2021, a compound +2.6%/yr. Reported net income was HK$318M in FY2025, compounding −2.1%/yr from FY2021.
Key figures
Market cap HK$1.1B (≈ $137M) Micro · P/E ratio 4.5 · P/S ratio 0.79 · Dividend yield 6.3% · Net margin 17.5% · Return on equity 11.0% · Return on assets (EBIT) 11.3% (5-year average) · Operating margin 17.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 61 out of 100 (low confidence).
What moves the price
The share trades about 57% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 200%, 1061 screens cheaper than that median.
Fair Value models
All 26 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch 1061, get fair value alerts →
Compare Essex Bio-Technology Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/B ratio by industry
- Net margin by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $80.79 | $113.53 | +41% | vs 1061 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥46.88 | ¥52.43 | +12% | vs 1061 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,900 | ₹1,983 | +4% | vs 1061 |
| Haleon plc HLN | $9.05 | $8.47 | −6% | vs 1061 |
| Merck KGaA MRK | €148.40 | €108.83 | −27% | vs 1061 |
| Galderma Group GALD | CHF 184.70 | CHF 112.46 | −39% | vs 1061 |
| Teva Pharmaceutical Industries Limited TEVA | $38.54 | $20.74 | −46% | vs 1061 |
| Takeda Pharmaceutical Company TAK | $21.41 | $11.23 | −48% | vs 1061 |
| Sandoz Group SDZ | CHF 81.24 | CHF 41.06 | −49% | vs 1061 |
| Divi's Laboratories Limited DIVISLAB | ₹11,178 | ₹1,567 | −86% | vs 1061 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Essex Bio-Technology Ltd (1061) overvalued or undervalued?
What is the fair value of 1061?
What is the quality score of 1061?
What is the price target for Essex Bio-Technology Ltd (1061)?
What is the Essex Bio-Technology Ltd stock forecast for 2026?
What is the revenue of Essex Bio-Technology Ltd (1061)?
Does Essex Bio-Technology Ltd pay a dividend?
How much is the dividend of Essex Bio-Technology Ltd (1061) and when is the ex-dividend date?
What growth is priced into Essex Bio-Technology Ltd (1061)?
What discount rate (WACC) does the fair value of 1061 use?
What is a reverse DCF?
How much growth has Essex Bio-Technology Ltd (1061) delivered so far?
How fast is the sector of Essex Bio-Technology Ltd (1061) growing?
What is the free cash flow yield of Essex Bio-Technology Ltd (1061)?
What is the intrinsic value of Essex Bio-Technology Ltd (1061)?
Is Essex Bio-Technology Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 1061?
How much is Essex Bio-Technology Ltd worth?
What do the bullish and bearish scenarios say about 1061?
What is the P/E ratio of 1061?
How solid is the balance sheet of Essex Bio-Technology Ltd (1061)?
How far is 1061 from its 52-week high?
Which stocks are comparable to Essex Bio-Technology Ltd?
Is Essex Bio-Technology Ltd stock attractive at the current price?
How is the fair value of 1061 calculated?
Is it still worth investing in stocks now?
What is the share price of Essex Bio-Technology Ltd (1061)?
What should I pay attention to with Essex Bio-Technology Ltd right now?
Where does the earnings growth of Essex Bio-Technology Ltd (1061) come from?
Key figures of Essex Bio-Technology Ltd
How large is the market capitalisation of Essex Bio-Technology Ltd (1061)?
What is the P/S ratio of Essex Bio-Technology Ltd (1061)?
What is the dividend yield of Essex Bio-Technology Ltd (1061)?
What is the net margin of Essex Bio-Technology Ltd (1061)?
What is the return on equity of Essex Bio-Technology Ltd (1061)?
What is the EBIT return on assets of Essex Bio-Technology Ltd (1061)?
What is the operating margin of Essex Bio-Technology Ltd (1061)?
How fast is revenue growing at Essex Bio-Technology Ltd (1061)?
How fast are earnings growing at Essex Bio-Technology Ltd (1061)?
How much net cash does Essex Bio-Technology Ltd (1061) hold?
Watch Essex Bio-Technology Ltd in the live analysis
One click puts Essex Bio-Technology Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.